IN2015DN02630A - - Google Patents

Info

Publication number
IN2015DN02630A
IN2015DN02630A IN2630DEN2015A IN2015DN02630A IN 2015DN02630 A IN2015DN02630 A IN 2015DN02630A IN 2630DEN2015 A IN2630DEN2015 A IN 2630DEN2015A IN 2015DN02630 A IN2015DN02630 A IN 2015DN02630A
Authority
IN
India
Prior art keywords
present disclosure
methods
disclosure relates
mammalian cells
increased levels
Prior art date
Application number
Other languages
English (en)
Inventor
Amit; Varma
James; Cuenca
Ying; Zhu
Original Assignee
Abbvie Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Biotherapeutics Inc filed Critical Abbvie Biotherapeutics Inc
Publication of IN2015DN02630A publication Critical patent/IN2015DN02630A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/005Glycopeptides, glycoproteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51Complete heavy chain or Fd fragment, i.e. VH + CH1
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/582Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IN2630DEN2015 2012-10-01 2013-09-27 IN2015DN02630A (cg-RX-API-DMAC7.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261708554P 2012-10-01 2012-10-01
PCT/US2013/062410 WO2014055370A1 (en) 2012-10-01 2013-09-27 Compostions and methods for producing glycoproteins

Publications (1)

Publication Number Publication Date
IN2015DN02630A true IN2015DN02630A (cg-RX-API-DMAC7.html) 2015-09-18

Family

ID=49354940

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2630DEN2015 IN2015DN02630A (cg-RX-API-DMAC7.html) 2012-10-01 2013-09-27

Country Status (28)

Country Link
US (2) US20150259425A1 (cg-RX-API-DMAC7.html)
EP (1) EP2904092B1 (cg-RX-API-DMAC7.html)
JP (1) JP6351598B2 (cg-RX-API-DMAC7.html)
KR (1) KR102182885B1 (cg-RX-API-DMAC7.html)
CN (1) CN104797707A (cg-RX-API-DMAC7.html)
AU (1) AU2013327681B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015007319B1 (cg-RX-API-DMAC7.html)
CA (1) CA2886753C (cg-RX-API-DMAC7.html)
CY (1) CY1119602T1 (cg-RX-API-DMAC7.html)
DK (1) DK2904092T3 (cg-RX-API-DMAC7.html)
EA (1) EA201590550A1 (cg-RX-API-DMAC7.html)
ES (1) ES2646594T3 (cg-RX-API-DMAC7.html)
HK (1) HK1207394A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20171753T1 (cg-RX-API-DMAC7.html)
HU (1) HUE034896T2 (cg-RX-API-DMAC7.html)
IL (1) IL237916A0 (cg-RX-API-DMAC7.html)
IN (1) IN2015DN02630A (cg-RX-API-DMAC7.html)
LT (1) LT2904092T (cg-RX-API-DMAC7.html)
ME (1) ME02882B (cg-RX-API-DMAC7.html)
MX (1) MX366106B (cg-RX-API-DMAC7.html)
NO (1) NO2760138T3 (cg-RX-API-DMAC7.html)
PL (1) PL2904092T3 (cg-RX-API-DMAC7.html)
PT (1) PT2904092T (cg-RX-API-DMAC7.html)
RS (1) RS56641B1 (cg-RX-API-DMAC7.html)
SG (2) SG11201502339YA (cg-RX-API-DMAC7.html)
SI (1) SI2904092T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201700588T1 (cg-RX-API-DMAC7.html)
WO (1) WO2014055370A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10376582B2 (en) 2013-10-16 2019-08-13 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
SG11201703446RA (en) * 2014-10-31 2017-05-30 Abbvie Biotherapeutics Inc Anti-cs1 antibodies and antibody drug conjugates
US10696735B2 (en) 2015-01-21 2020-06-30 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
MX2018008447A (es) * 2016-01-06 2019-05-30 Oncobiologics Inc Modulacion de especies afucosilados en una composicion de anticuerpo monoclonal.
CN109153717A (zh) * 2016-01-06 2019-01-04 安口生物公司 减少单克隆抗体组合物中的高分子量物类、酸性电荷物类和片段
MX2018009341A (es) 2016-02-03 2019-05-15 Oncobiologics Inc Formulaciones tamponadas para una mayor estabilidad de anticuerpos.
SG11201806335RA (en) * 2016-02-22 2018-09-27 Agency Science Tech & Res Cell culture medium
US11453858B2 (en) 2016-11-11 2022-09-27 Whitehead Institute For Biomedical Research Human plasma-like medium
CN111954719B (zh) 2018-03-26 2025-07-18 美国安进公司 细胞培养物中产生的抗体的总去岩藻糖基化糖型
US20210230289A1 (en) 2018-06-12 2021-07-29 The Regents Of The University Of California Single-chain bispecific chimeric antigen receptors for the treatment of cancer
CA3137101A1 (en) * 2019-04-18 2020-10-22 Janssen Biotech, Inc. Sialylated glycoproteins
CN111944050B (zh) * 2020-08-19 2022-05-13 苏州普乐康医药科技有限公司 一种抗b7-h3抗体及其应用
CN113337562B (zh) * 2021-05-24 2022-06-03 宁波人健药业集团股份有限公司 使用CHO细胞高效发酵生产rhCG的方法
CN113480632B (zh) * 2021-07-30 2023-02-03 宁波人健药业集团股份有限公司 一种在CHO细胞中表达的重组蛋白rhCG纯化工艺

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
DE69233745D1 (de) 1991-12-02 2008-10-23 Cambridge Antibody Tech Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
US7227002B1 (en) 1997-04-14 2007-06-05 Micromet Ag Human antibodies that bind human 17-A1/EpCAM tumor antigen
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
ATE420945T1 (de) * 2001-02-15 2009-01-15 Centocor Inc Chemisch definiertes medium für kultivierte säugerzellen
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
CA2560508A1 (en) 2004-03-24 2005-10-06 Pdl Biopharma, Inc. Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
CN102006886A (zh) 2007-08-03 2011-04-06 菲赛特生物技术公司 抗-tweak受体抗体的治疗用途

Also Published As

Publication number Publication date
IL237916A0 (en) 2015-05-31
US20150259425A1 (en) 2015-09-17
PL2904092T3 (pl) 2018-02-28
JP6351598B2 (ja) 2018-07-04
ES2646594T3 (es) 2017-12-14
NO2760138T3 (cg-RX-API-DMAC7.html) 2018-08-04
SI2904092T1 (en) 2018-01-31
KR20150063441A (ko) 2015-06-09
CA2886753C (en) 2021-01-26
JP2015532096A (ja) 2015-11-09
CY1119602T1 (el) 2018-04-04
CN104797707A (zh) 2015-07-22
SG10201702448WA (en) 2017-04-27
RS56641B1 (sr) 2018-03-30
HK1207394A1 (en) 2016-01-29
EP2904092A1 (en) 2015-08-12
SMT201700588T1 (it) 2018-01-11
EP2904092B1 (en) 2017-09-20
AU2013327681A1 (en) 2015-04-09
MX2015004027A (es) 2015-10-29
US20170152540A1 (en) 2017-06-01
BR112015007319A2 (pt) 2017-08-08
LT2904092T (lt) 2017-12-11
ME02882B (me) 2018-04-20
BR112015007319B1 (pt) 2022-02-15
AU2013327681B2 (en) 2019-01-24
CA2886753A1 (en) 2014-04-10
HUE034896T2 (hu) 2018-03-28
KR102182885B1 (ko) 2020-11-25
MX366106B (es) 2019-06-27
EA201590550A1 (ru) 2015-09-30
DK2904092T3 (en) 2017-12-11
SG11201502339YA (en) 2015-04-29
HRP20171753T1 (hr) 2017-12-29
PT2904092T (pt) 2017-12-06
WO2014055370A1 (en) 2014-04-10

Similar Documents

Publication Publication Date Title
IN2015DN02630A (cg-RX-API-DMAC7.html)
IL288509A (en) Mammalian cell culture
MY169935A (en) "a method for reducing heterogeneity of antibodies and a process of producing the antibodies thereof"
MY161726A (en) Biological methods for preparing adipic acid
MY181513A (en) Cell culture compositions and methods for polypeptide production
PH12014500588A1 (en) Microorganisms and methods for producing alkenes
IN2014DN09244A (cg-RX-API-DMAC7.html)
MX2014015768A (es) Microorganismo recombinante para la produccion fermentativa de metionina.
WO2015004403A3 (fr) Procede de culture cellulaire decouple
MX345399B (es) Metodo de cultivo de celulas animales.
MX2015011781A (es) Medio de cultivo celular y metodos de produccion de anticuerpos.
NZ703973A (en) Complex chromosome engineering for production of human antibodies in transgenic animals
EP2582792A4 (en) HEART OF CARDIOMYOCYTES WITH DIALYSATED SERUM
PH12014501019A1 (en) Kit comprising serum replacement and labile factors
MX344896B (es) Método de operación de la fermentación de un substrato gaseoso que contiene monóxido de carbono.
MY180645A (en) Microbial production of fatty amines
WO2014049382A3 (en) Ethylenediamine fermentative production by a recombinant microorganism
IN2014MN01621A (cg-RX-API-DMAC7.html)
MX353243B (es) Metodo para incrementar la secrecion de proteinas recombinantes.
UA71656U (ru) Способ диагностики эндогенной интоксикации
GB201119202D0 (en) Device and method
GB201105503D0 (en) Microcarrier for the culture if stem cells, method of culturing stem cells and method of using said microcarrier